$FURX News

Last published 12y ago

12y agoASDN HGSI HLS VG+26Pershing Square Proposes Independent Slate For Allergan Board of DirectorsBusiness WireNEW YORK--(BUSINESS WIRE)--Pershing Square Capital Management, L.P. (“Pershing Square”) today announced a slate of six highly experienced, independent directors for the board of directors of Allergan, Inc. (“Allergan”). The six members of the slate are: Betsy Atkins, Cathleen P. Black, Fredric N. Eshelman, Steven J. Shulman, David A. Wilson and John J. Zillmer.
12y agoFURX ACTFuriex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed MergerBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its ac ...
12y agoFURXFuriex Pharmaceuticals Reports First Quarter 2014 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) today reported its financial and operating results for the quarter ended March 31, 2014.
12y agoFURX FRXLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Furiex Pharmaceuticals, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”) (NASDAQ:FURX) concerning the proposed acquisition of the Company by Forest Laboratories, Inc. (“Forest”) (NYSE:FRX). Under the terms of the definitive merger agreement, Furiex stockholders will receive $95 per share in cash and ...
12y agoFURX FRXNewman Ferrara LLP Announces Investigation of Furiex Pharmaceuticals, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP is investigating potential claims against the board of directors of Furiex Pharmaceuticals, Inc. (“Furiex”) (Nasdaq:FURX) concerning the proposed sale of Furiex to Forest Laboratories Inc. (“Forest”) (NYSE:FRX).
12y agoFRX FURXForest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI)Business WireNEW YORK & MORRISVILLE, N.C.--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) and Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent ...
12y agoFURXFuriex Pharmaceuticals Announces First Quarter 2014 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its first quarter 2014 financial results on Wednesday, May 7, 2014, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
12y agoFURXFuriex Pharmaceuticals Announces Acceptance to Late-Breaking Abstract Session at Digestive Disease Week 2014Business WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results from its two Phase III clinical trials of eluxadoline in patients with diarrhea-predominant irritable bowel syndrome will be presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW) 2014, to be held May 3-6 at McCormick Place in Chicago, IL.
12y agoFURXFuriex Pharmaceuticals Confirms Takeda Will Present Additional Data from the EXAMINE Trial at the American College of Cardiology’s 63rd Annual Scientific SessionBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that its partner Takeda Pharmaceuticals Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in ...
12y agoFURXFuriex Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter and year ended December 31, 2013.
12y agoFURXFuriex Pharmaceuticals Confirms Takeda’s Submission of a New Drug Application for Trelagliptin Succinate (SYR-472) in Japan for the Treatment of Type 2 DiabetesBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for trelagliptin succinate (SYR-472), a once weekly dosage treatment for type 2 diabetes.
12y agoFURXFuriex Pharmaceuticals Announces Fourth Quarter 2013 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter 2013 financial results on Tuesday, March 11, 2014, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
12y agoFURXFuriex Pharmaceuticals Announces Positive Top-Line Results of Two Pivotal Phase III Clinical Trials of Eluxadoline in Patients with IBS-dBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formall ...
13y agoFURXFuriex Reports Third Quarter 2013 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.
13y agoFURXFuriex Pharmaceuticals Announces Priligy® Launch in the United Kingdom by MenariniBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, today announced it will receive a $5.0 million milestone payment from the Menarini Group for the launch of Priligy in the United Kingdom. Currently, Priligy is marketed for on-demand treatment of premature ejaculation in over 20 countries in Europe, Asia and Latin America, and ...
13y agoFURXFuriex Pharmaceuticals Announces Management ChangesBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) announced today the appointment of Sailash Patel to the position of Chief Financial Officer, effective November 15, 2013. Mr. Patel replaces Mr. Marshall Woodworth, who tendered his resignation to pursue other opportunities, but will remain with the company to assist during a transition period.
13y agoFURXFuriex Pharmaceuticals Announces Third Quarter 2013 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its third quarter 2013 financial results on Tuesday, November 5, 2013, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
13y agoFURXFuriex Pharmaceuticals Enters into a Loan Agreement for $15 Million and Restructures Its Existing Secured LoanBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) announced today it has executed a $15 million debt financing transaction with Fred Eshelman, Pharm.D., chairman and a 27.5% shareholder of Furiex. In parallel, Furiex has also entered into a Second Amended and Restated Loan and Security Agreement with MidCap Financial, LLC and Silicon Valley Bank to restructure its exis ...
13y agoFURXFuriex Confirms Takeda Receives European Marketing Authorization for VIPIDIA™ (alogliptin), VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone)Business WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed Takeda Pharmaceutical Company Limited (Takeda)’s announcement that the European Commission has granted Marketing Authorization (MA) for VIPIDIA™ (alogliptin) for the treatment of Type 2 diabetes patients who are uncontrolled on existing therapies and for the fixed-dose combinations VIPDOMET™ (alogliptin ...
13y agoFURXFuriex Confirms Alogliptin Cardiovascular Safety Outcomes Trial (EXAMINE) Met Primary EndpointBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited (Takeda) announced top line results of the EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial showing the primary endp ...
13y agoFURXFuriex Reports Second Quarter 2013 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended June 30, 2013.
13y agoFURXFuriex Confirms Takeda Receives Positive CHMP Opinion for VIPIDIA™ (alogliptin) and Fixed-Dose Combinations VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone)Business WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited (Takeda) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for VIPIDIA™ (alogliptin) and Fixed-Dose Combinations VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (aloglip ...
13y agoFURXFuriex Pharmaceuticals Announces Completion of Patient Enrollment for Its Phase III Clinical Trials of Eluxadoline for IBS-dBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company’s two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014 ...
13y agoFURXFuriex Pharmaceuticals Announces Second Quarter 2013 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its second quarter 2013 financial results on Tuesday, August 6, 2013, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
13y agoFURXFuriex Reports First Quarter 2013 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended March 31, 2013.
13y agoFURXFuriex Pharmaceuticals Announces First Quarter 2013 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its first quarter 2013 financial results on Tuesday, May 7, 2013, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
13y agoFURXFuriex Pharmaceuticals to Receive Milestone Payment for Priligy® Launch in FranceBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, today announced it will receive a $5.0 million milestone payment from the Menarini Group for the launch of Priligy in France. Currently, Priligy is marketed for on-demand treatment of premature ejaculation in 16 countries in Europe, Asia and Latin America, and is approved for ...
13y agoFURXFuriex Reports Fourth Quarter and Full Year 2012 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter and year ended December 31, 2012.
13y agoFURXFuriex Pharmaceuticals to Present at Cowen & Company 33rd Annual Healthcare ConferenceBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, announced today that June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex, is scheduled to present at the Cowen 33rd Annual Healthcare Conference in Boston, MA on Monday, March 4, 2013 at 2:10 p.m. ET. Dr. Almenoff will provide a corporate overview and dis ...
13y agoFURXFuriex Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2)Business WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced today that avarofloxacin (USAN adopted, INN approval pending), has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA). Avarofloxacin is a Phase III-ready broad-spectrum fluoroquinolone antibiotic for the treatment of acute bact ...
13y agoFURXFuriex Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter and full year 2012 financial results on Wednesday, March 6, 2013, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
13y agoFURXFuriex Confirms Takeda’s Receipt of FDA Approval of NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the Treatment of Type 2 DiabetesBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.S. Food and Drug Administration of three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatme ...
14y agoFURXFuriex Reports Third Quarter 2012 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2012.
14y agoFURXFuriex Pharmaceuticals Announces Third Quarter 2012 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its third quarter 2012 financial results on Thursday, November 1, 2012, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
14y agoFURXFuriex Reports Second Quarter 2012 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended June 30, 2012. Furiex was spun off from Pharmaceutical Product Development, Inc. (PPD) as a separate public company effective June 14, 2010. Furiex continues the compound partnering business started by PPD in 1998.
14y agoFURX SIVBFuriex Pharmaceuticals Amends Current Loan and Security Agreement, Adding an Additional $30.0 MillionBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced today it has restructured its Loan and Security Agreement (Agreement) with MidCap Financial LLC and Silicon Valley Bank to add $30.0 million in capital to the existing $10.0 million loan.
14y agoFURXFuriex Pharmaceuticals Announces Closing of Priligy® Asset Transfer and License AgreementsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced it has completed the closings under the previously announced Asset Transfer Agreement with ALZA Corporation and Janssen Pharmaceutica, NV (Janssen) for worldwide Priligy® product rights and the License Agreement with Menarini Group for Priligy commercialization in Europe, most of Asia, Africa, Latin Ame ...
14y agoFURXFuriex Confirms Takeda’s Resubmissions of Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone NDAs to the U.S. FDABusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazo ...
14y agoFURXFuriex Pharmaceuticals Announces Second Quarter 2012 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its second quarter 2012 financial results on Thursday, August 2, 2012, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
14y agoFURXFuriex Pharmaceuticals Announces First Patient Dosed in Phase III Clinical Trials of MuDelta in Diarrhea-Predominant Irritable Bowel SyndromeBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Furiex is conducting two simultaneous Phase III trials, one ...
14y agoFURXFuriex Confirms Takeda’s Announcement on the Acceptance of the EMA Submissions for Two Fixed-Dose Alogliptin Combination Therapies for the Treatment of Type 2 DiabetesBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Global Research & Development Centre (Europe) Ltd. received confirmation from the European Medicines Agency (EMA) of the acceptance of submissions of Marketing Authorization Applications (MAAs) for alogliptin and pioglitazone combined in a single tablet and alogliptin and metformin combined ...
14y agoFURXFuriex Confirms Takeda’s Announcement on the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 DiabetesBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Global Research & Development Centre (Europe) Ltd. received confirmation on the acceptance of the submission of a Marketing Authorization Application, or MAA, from the European Medicines Agency for alogliptin, a selective dipeptidyl peptidase IV, or DPP-4, inhibitor for the treatment of type ...
14y agoFURXFuriex Pharmaceuticals and Menarini Announce License Agreement for Priligy®Business WireMORRISVILLE, N.C. & FLORENCE, ITALY--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) and Menarini Group today announced that they have entered into a license agreement by which Furiex will license to Menarini rights to commercialize Priligy® in Europe, most of Asia, Africa, Latin America and the Middle East. Furiex will retain full development and commercialization rights in the Unite ...
14y agoFURXFuriex Pharmaceuticals Announces Agreement to Transfer Priligy® Product RightsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced that it has entered into an agreement with ALZA Corporation and Janssen Pharmaceutica, N.V. whereby ALZA and Janssen will transfer worldwide rights for Priligy® to Furiex. Currently Priligy is marketed by Janssen for on-demand treatment of premature ejaculation in 15 countries in Europe, Asia and Latin Americ ...
14y agoFURXFuriex Reports First Quarter 2012 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended March 31, 2012. Furiex was spun off from Pharmaceutical Product Development, Inc. (PPD) as a separate public company effective June 14, 2010. Furiex continues the compound partnering business started by PPD in 1998.
14y agoFURXFuriex Confirms Takeda’s Receipt of Complete Response Letter from the FDA for Alogliptin and Fixed-Dose Combination Alogliptin and PioglitazoneBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug applications (NDAs) for alogliptin, and the fixed-dose combination therapy alogliptin and pioglitazone.
14y agoFURXFuriex Pharmaceuticals Announces First Quarter 2012 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its first quarter 2012 financial results on Thursday, May 3, 2012, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
14y agoFURXFuriex Reports Fourth Quarter and Full Year 2011 Financial ResultsBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial and operating results for the quarter and year ended December 31, 2011. Furiex was spun off from PPD, Inc. as a separate public company effective June 14, 2010. As a result, the Furiex financial information prior to that date was derived from PPD's discovery sciences segment and does not re ...
14y agoFURXFuriex Announces that the European Commission Endorses Positive Opinion of Priligy™ for the On-Demand Treatment of Premature Ejaculation in all European Union CountriesBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced that the European Commission endorsed the positive opinion adopted by the Committee for Human Medicinal Products (CHMP) on October 18, 2011 for Priligy™ (dapoxetine) 30 mg and 60 mg doses. Pending national approvals, the marketing authorization for the Priligy doses can be granted in the European Union ...
14y agoFURXFuriex Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Earnings Release and Conference CallBusiness WireMORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its fourth quarter and full year 2011 financial results on Tuesday, February 21, 2012, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.